公开(公告)号：EP2899206A1

公开(公告)日：2015-07-29

申请号：EP15154297.4

申请日：2009-05-14

申请人： immatics biotechnologies GmbH

发明人： Stevanovic, Stefan ,  Gouttefanges, Cécile ,  Rammensee, Hans-Georg ,  Weinschenk, Toni ,  Lewandrowski, Peter

IPC分类号： C07K14/47 ,  C07K16/18 ,  C12N15/12 ,  A61K38/00 ,  G01N33/50

CPC分类号： A61K38/10 ,  A61K39/0011 ,  C07H21/00 ,  C07K7/08 ,  C07K14/4747 ,  C07K14/4748 ,  C07K14/7056 ,  C07K16/18 ,  C12N15/10 ,  C12N15/86

摘要： The present invention relates to peptides, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to two novel peptide sequences derived from HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

摘要翻译： 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及存活蛋白衍生的肿瘤相关细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明具体涉及可以用于引发抗肿瘤免疫应答的疫苗组合物中的两种源自人类肿瘤细胞的HLA II类分子的新型肽序列。